Dein erstes Forum » characterized by inability to complet

by NiravGokani · February 26, 2019


Researchmoz added Most up-to-date research on “Chronic Respiratory Disease Drug Development Pipeline Review, 2018” to its huge collection of research reports.


This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma Bryan Rust Jersey , chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Get Free PDF Brochure For More Technical Insights@ ;repid=1957070


Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight Justin Schultz Jersey , smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.


COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs Olli Maatta Jersey , leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.


IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath Mario Lemieux Jersey , especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections Sidney Crosby Penguins Jersey , family history and abnormal acid reflux. There are 136 products in development for this indication.


Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.

View Complete TOC with tables & Figures @

Scope


Which companies are the most active within each pipeline?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline Jake Guentzel Penguins Jersey , compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in this disease area?